≥98% (HPLC), powder

2-Amino-1,4-dihydro-6-methyl-4-(3 nitrophenyl)-3,5-pyridinedicarboxylic acid 3-[1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethyl) ester, CS-905, RS-9054
Empirical Formula (Hill Notation):
Número de CAS:
Peso molecular:
MDL number:
PubChem Substance ID:

Quality Level


≥98% (HPLC)




DMSO: >10 mg/mL



storage temp.

room temp

SMILES string




InChI key



Azelnidipine is a novel dihydropyridine derivative, a L-type calcium channel blocker, and an antihypertensive. Acute administration of azelnidipine prevents a sudden drop of cardiac function after acute stress. Azelnidipine may have a protective role in inflammation associated with atherosclerosis.


10, 50 mg in glass bottle

Biochem/physiol Actions

Azelnidipine, a novel dihydropyridine derivative, is a L-type calcium channel blocker and antihypertensive. Unlike other L-type calcium channel blockers, azelnidipine causes minimal stimulation of the sympathetic nervous system despite its significant depressor effect. Azelnidipine may have a protective role in inflammation in atherosclerosis.


CorrosionExclamation mark



Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves


NONH for all modes of transport

WGK Germany


Flash Point F

Not applicable

Flash Point C

Not applicable

Yoshio Matsui et al.
American journal of hypertension, 25(8), 862-868 (2012-06-01)
We aimed to investigate the association of the change in the ambulatory arterial stiffness index (AASI) with that in carotid-femoral pulse wave velocity (cfPWV) during treatment with antihypertensive medication. We enrolled 207 hypertensive patients treated with olmesartan monotherapy for 12...
Yoshio Matsui et al.
Hypertension (Dallas, Tex. : 1979), 59(6), 1132-1138 (2012-05-02)
Day-by-day home blood pressure (BP) variability (BPV) was reported to be associated with increased cardiovascular risk. We aimed to test the hypothesis that the angiotensin II receptor blocker/calcium-channel blocker combination decreases day-by-day BPV more than the angiotensin II receptor blocker/diuretic...
Hiroyuki Daikuhara et al.
Diabetes & vascular disease research, 9(4), 280-286 (2012-06-22)
Angiotensin II receptor blockers (ARB) are often co-administered with a calcium channel blocker (CCB) for treating hypertension. In this open-label randomised study, untreated diabetic hypertensive patients were randomised to receive either olmesartan 20 mg/day or candesartan 8 mg/day for 12...
Ikuo Saito et al.
Journal of nephrology, 25(5), 699-708 (2011-10-25)
In the present investigation we extracted data on hypertensive patients with chronic kidney disease (CKD) who were enrolled in 3 studies - 2 studies of the angiotensin receptor blocker (ARB) olmesartan medoxomil (OLM), lasting 12 weeks and 2 years, respectively...
Takeshi Takami et al.
Vascular health and risk management, 7, 383-390 (2011-07-29)
The aim of this study was to compare the effects of olmesartan combined with either azelnidipine or amlodipine on central blood pressure (CBP) and left ventricular mass index (LVMI) in hypertensive patients. Patients with brachial systolic BP ≥ 140 mmHg...
We offers many products related to calcium channels for your research needs.
Más información

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.